The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous non-Hodgkin lymphoma.
• Accurate prognostic tools are crucial for guiding treatment decisions in DLBCL patients receiving R-CHOP chemotherapy.

Purpose of the Study:

• To validate the prognostic significance of the SIL index in a larger cohort of DLBCL patients.
• To assess the utility of the SIL index for risk stratification in DLBCL.

Main Methods:

• Retrospective analysis of a large cohort of DLBCL patients treated with R-CHOP.
• Evaluation of the SIL index components: advanced stage (S), soluble interleukin-2 receptor (I), and lactate dehydrogenase (L).
• Statistical analysis to determine the association between SIL index and progression-free survival (PFS).

Main Results:

• The SIL index independently predicted progression-free survival (PFS) in DLBCL patients.
• Five-year PFS rates were significantly higher in the standard-risk group (79%) compared to the high-risk group (53%) (p < 0.0001).
• The SIL index demonstrated prognostic utility across different age groups and extranodal involvement sites.

Conclusions:

• The SIL index is a simple, objective, and validated prognostic tool for DLBCL patients.
• It aids in effective risk stratification, enabling personalized treatment strategies for DLBCL.